Trial Profile
A PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL GROUP, PROOF OF CONCEPT STUDY OF THE ANALGESIC EFFECTS OF RN624 IN ADULT PATIENTS WITH POST-HERPETIC NEURALGIA
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Tanezumab (Primary)
- Indications Postherpetic neuralgia
- Focus Therapeutic Use
- 13 Jan 2009 Planned number of patients changed from 129 to 99 as reported by ClinicalTrials.gov.
- 13 Jan 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
- 13 Jan 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.